NCT02537509 (PRADA) is a Phase 2 clinical trial of Cholecalciferol in Atopic Dermatitis, sponsored by Rennes University Hospital.

Who is sponsoring NCT02537509?

NCT02537509 is sponsored by Rennes University Hospital.

What drugs are being tested in NCT02537509?

Interventions in NCT02537509: Cholecalciferol, Placebo of cholecalciferol.

What condition does NCT02537509 study?

NCT02537509 studies Atopic Dermatitis.

Is NCT02537509 still recruiting?

NCT02537509 is currently completed. Last updated 23 March 2023.

Last reviewed 2023-03-23 · How we verify

NCT02537509: PRADA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PRAgmatic Trial in Atopic Dermatitis Testing Long-term Control Effectiveness of New Phototherapy Regimen During Winter Coupled With Oral Vitamin D Supplementation vs. Placebo

Completed Phase 2 Last updated 23 March 2023

What this trial tests

Phase 2 trial testing Cholecalciferol in Atopic Dermatitis in 111 participants. Completed in 3 March 2023.

Timeline

27 October 2015

Primary endpoint
3 March 2023

3 March 2023

Quick facts

Lead sponsor	Rennes University Hospital
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	111
Start date	27 October 2015
Primary completion	3 March 2023
Estimated completion	3 March 2023
Sites	11 locations across France

Drugs / interventions tested

Cholecalciferol (cholecalciferol) — full drug profile →
Placebo of cholecalciferol — full drug profile →

Conditions studied

Atopic Dermatitis — all drugs for Atopic Dermatitis →

Sponsor

Rennes University Hospital

Who can join

15 and older, any sex, with Atopic Dermatitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Spaced phototherapy sessions during winter as add-on therapy in combination with vitamin D supplementation or not, could be beneficial to improve disease LTC in AD patients

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A new phototherapy regimen during winter as an add-on therapy, coupled with oral vitamin D supplementation, for the long-term control of atopic dermatitis: study protocol for a multicentre, randomized, crossover, pragmatic trial - the PRADA trial.
Droitcourt C, Barbarot S, Maruani A, Darrieux L, et al · · 2019 · cited 2× · PMID 30909923 · DOI 10.1186/s13063-019-3276-9

Verify or expand the search:

Other trials of Cholecalciferol

Trials testing the same drug.

NCT06847373 — Efficacy and Safety of Vitamin D Supplementation in Pediatric Patients with Obesity · NA · recruiting
NCT06447441 — Clinical Outcomes Of Mega-dosage Supplementations Of Cholecalciferol In Critically Ill Patients With Sepsis · NA · not yet recruiting
NCT06301178 — Effect of Vitamin D Injection on Hypertrophic Scars and Keloids · Phase 1, PHASE2 · completed
NCT06053281 — The Role of Vitamin D in Neuroinflammatory on Drug Resistant Epilepsy · EARLY_PHASE1 · unknown
NCT05860270 — Oral Vitamin D Supplementation Prevent Peritoneal Dialysis-related Peritonitis · Phase 4 · recruiting

Other recruiting trials for Atopic Dermatitis

Currently open trials in the same condition.

NCT07262983 — Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopi · Phase 1 · recruiting
NCT07445919 — A Clinical Study to Evaluate SM17 for Atopic Dermatitis · Phase 2 · recruiting
NCT07488065 — A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants · Phase 1 · recruiting
NCT07467564 — The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatit · recruiting
NCT07358156 — A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and E · Phase 1 · recruiting

Other Rennes University Hospital trials

Trials by the same sponsor.

NCT07527949 — PASTRAMI : Patient-specific Statistics for Microstructure-augmented Connectomics · NA · not yet recruiting
NCT07449832 — Sperm Epigenome in Hodgkin Lymphoma · NA · not yet recruiting
NCT06950398 — Normothermic Oxygenated Perfusion (NMP) Viability Testing Before Transplantation of Discarded Livers · Phase 2 · not yet recruiting
NCT07188753 — Randomized Controlled Trial Testing the Efficacy of Transcranial Magnetic Stimulation by Accelerated & High-dose Theta-b · NA · not yet recruiting
NCT06898099 — Evaluation of the Efficacy of E2R Hypnotherapy in the Management of Chronic Insomnia in Primary Care (HypERR) · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02537509 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rennes University Hospital
Last refreshed: 23 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02537509.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing